INFLUENCE OF DIFFERENT DOSES OF INTERFERON-ALPHA-2B ON THE BLOOD-PLASMA LEVELS OF 5-FLUOROURACIL

被引:9
作者
CZEJKA, MJ [1 ]
SCHULLER, J [1 ]
JAGER, W [1 ]
FOGL, U [1 ]
WEISS, C [1 ]
机构
[1] HOSP RUDOLFSTIFTUNG,DEPT MED 1,VIENNA,AUSTRIA
关键词
PHARMACOKINETICS; 5-FLUOROURACIL; INTERFERON-ALPHA-2B; DOSE ESCALATION; PATIENTS;
D O I
10.1007/BF03188803
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The blood plasma levels of 5-fluorouracil (5FU) after i.v. administration have been determined without and under the influence of 1, 5 or 9 million units (MU) preadministered interferon (IFN) in patients with gastrointestinal carcinoma. The co-administration of 9 MU IFN causes a doubled increase of the 5FU serum concentrations combined with a statistically significant change of the pharmacokinetics of 5FU for c(0), AUC, Vd and Cl-tot (P < 0.005). A similar effect with distinctly increased serum concentrations could be observed for the preadministration of 5 mU IFN whereby c(0) and AUC were elevated significantly (P < 0.05), but not Vd, CL(tot) and cd. The preadministration of 1 MU IFN also leads to higher plasma levels, but no changes in the pharmacokinetics of 5FU could be calculated (P > 0.05). A linear correlation between the IFN dose and the pharmacokinetic parameters c(0) (R = 0.958), AUC(0-120) (R = 0.948), Vd (R = 0.941) and Cl-tot (R = 0.963) of 5FU could be found (P < 0.05), but not for the coefficient of distribution and t(1/2)el. The results indicate that the pharmacokinetics of 5FU might be influenced by the preadministered IFN dose.
引用
收藏
页码:247 / 250
页数:4
相关论文
共 9 条
[1]  
CHU E, 1990, CANCER RES, V50, P5834
[2]  
CZEJKA M, 1993, DRUG RES, V43, P387
[3]  
CZEJKA MJ, 1991, PHARMAZIE, V46, P817
[4]  
CZEJKA MJ, 1991, DRUG RES, V41, P860
[5]   RAPID AND SIMPLE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR 5'-FLUOROURACIL IN PLASMA FOR BIOAVAILABILITY STUDIES [J].
JAGER, W ;
CZEJKA, MJ ;
SCHULLER, J ;
FOGL, U ;
CZEJKA, E ;
LACKNER, H .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1990, 532 (02) :411-417
[6]  
KEMENY N, 1990, P AM SOC CLIN ONCOL, V9, P420
[7]  
SCHULLER J, 1991, ACTA CHIR AUSTRIACA, V23, P214
[8]  
WADLER S, 1990, SEMIN ONCOL, V17, P16
[9]  
WADLER S, 1990, CANCER RES, V50, P5735